These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23950585)

  • 1. Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
    Tasset I; Bahamonde C; Agüera E; Conde C; Cruz AH; Pérez-Herrera A; Gascón F; Giraldo AI; Ruiz MC; Lillo R; Sánchez-López F; Túnez I
    Pharmacol Rep; 2013; 65(3):624-31. PubMed ID: 23950585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
    Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I
    Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
    Tasset I; Aguera E; Gascon F; Giraldo AI; Salcedo M; Cruz AH; Sanchez F; Tunez I
    Rev Neurol; 2012 Apr; 54(8):449-52. PubMed ID: 22492096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
    Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H
    Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is natalizumab a breakthrough in the treatment of multiple sclerosis?
    Doggrell SA
    Expert Opin Pharmacother; 2003 Jun; 4(6):999-1001. PubMed ID: 12783595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab therapy for multiple sclerosis.
    Chataway J; Miller DH
    Neurotherapeutics; 2013 Jan; 10(1):19-28. PubMed ID: 23307290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral oxidative stress in relapsing-remitting multiple sclerosis.
    Tasset I; Agüera E; Sánchez-López F; Feijóo M; Giraldo AI; Cruz AH; Gascón F; Túnez I
    Clin Biochem; 2012 Apr; 45(6):440-4. PubMed ID: 22330938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.
    Sangalli F; Moiola L; Bucello S; Annovazzi P; Rizzo A; Radaelli M; Vitello G; Grimaldi LM; Ghezzi A; Martinelli V; Comi G
    Neurol Sci; 2011 Jan; 31 Suppl 3():299-302. PubMed ID: 20544247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Natalizumab as induction therapy in multiple sclerosis].
    Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P
    Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"].
    Popova EV; Brylev LV; Davydovskaia MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):79-82. PubMed ID: 23528599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
    Pilz G; Harrer A; Oppermann K; Wipfler P; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    Mult Scler; 2012 Apr; 18(4):506-9. PubMed ID: 21965415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
    Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P
    J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis.
    Escribano BM; Aguilar-Luque M; Bahamonde C; Conde C; Lillo R; Sanchez-Lopez F; Giraldo AI; Cruz AH; Luque E; Gascon F; Aguera E; Tunez I
    Curr Pharm Des; 2016; 22(31):4876-4880. PubMed ID: 27396595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.